Drug reference

Vernakalant

Antiarrhythmic

Also known as Vernakalant hydrochloride, Brinavess

Antiarrhythmic

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Vernakalant blocks potassium and sodium channels, primarily in the atria. This action helps to restore normal heart rhythm. It also exhibits some calcium channel blocking effects and influences pacemaker activity.

Indications

Rapid conversion of recent onset atrial fibrillation to sinus rhythm (specialist supervision in hospital)

Dosing

Adult: IV infusion, initially 3 mg/kg (max 339 mg/dose) over 10 minutes. If conversion to sinus rhythm does not occur within 15 minutes after initial infusion, a second dose of 2 mg/kg (max 226 mg/dose) may be given over 10 minutes. Dilution: For body-weight up to and including 100 kg, dilute to a concentration of 4 mg/mL with 100 mL of Glucose 5%, Sodium Chloride 0.9%, or Lactated Ringer’s Solution.…
Max dose: 5 mg/kg per 24 hours; 565 mg per day

Contraindications

Acute coronary syndrome within the last 30 days
Baseline QT interval 440 milliseconds or greater
Congestive heart failure with left ventricular ejection fraction < 35%
Heart failure (New York Heart Association class III/IV)
Second- or third-degree heart block (unless pacemaker fitted)
Severe aortic stenosis
Severe bradycardia
Sinus node dysfunction
Systolic blood pressure less than 100 mmHg

Side effects

Common

ArrhythmiasCoughDizzinessFeeling hotHeadacheHypotensionNasal complaintsNauseaOral disordersSensation abnormalSkin reactionsSweat changesTaste alteredVomiting

Serious